Chemical formula: C₅₄H₆₉N₁₁O₁₀S₂ Molecular mass: 1,096.33 g/mol PubChem compound: 71349
Lanreotide interacts in the following cases:
The limited published data available indicate that somatostatin analogues may decrease the metabolic clearance of compounds known to be metabolised by cytochrome P450 enzymes, which may be due to the suppression of growth hormone. Since it cannot be excluded that lanreotide may have this effect, other drugs mainly metabolised by CYP3A4 and which have a low therapeutic index (e.g. quinidine, terfenadine) should therefore be used with caution.
Pharmacological studies in animals and humans show that lanreotide, like somatostatin and other somatostatin analogues, inhibits the secretion of insulin and glucagon. Any anti-diabetic treatment should be adjusted accordingly.
Concomitant administration of bradycardia inducing drugs (e.g. beta blockers) may have an additive effect on the slight reduction of heart rate associated with lanreotide. Dose adjustments of such concomitant medicines may be necessary.
Limited published data indicate that concomitant administration of somatostatin analogues and bromocriptine may increase the availability of bromocriptine.
The pharmacological gastrointestinal effects of lanreotide may result in the reduction of the intestinal absorption of co-administered drugs including ciclosporin. Concomitant administration of ciclosporin with lanreotide may decrease the relative bioavailability of ciclosporin and therefore may necessitate the adjustment of ciclosporin dose to maintain therapeutic levels.
There is a limited amount of data (less than 300 pregnancy outcomes) from the use of lanreotide in pregnant women.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity.
As a precautionary measure, it is preferable to avoid the use of lanreotide during pregnancy.
It is not known whether lanreotide is excreted in human milk. A risk to the newborns/infants cannot be excluded. Lanreotide should not be used during breast-feeding.
Reduced fertility was observed in female rats due to the inhibition of GH secretion at doses in excess of those achieved in humans at therapeutic doses.
Lanreotide has minor or moderate influence on the ability to drive and use machines. No studies on the effects on the ability to drive and use machines have been performed. However, dizziness has been reported with lanreotide. If a patient is affected, he/she should not drive or operate machinery.
Undesirable effects reported by patients suffering from acromegaly and GEP-NETs treated with lanreotide in clinical trials are listed under the corresponding body organ systems according to the following classification: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100), not known (cannot be estimated from the available data).
The most commonly expected adverse drug reactions following treatment with lanreotide are gastrointestinal disorders (most commonly reported are diarrhoea and abdominal pain, usually mild or moderate and transient), cholelithiasis (often asymptomatic) and injection site reactions (pain, nodules and indurations).
The profile of undesirable effects is similar for all indications.
| System organ class | Very common (≥1/10) | Common (≥1/100 to <1/10) | Uncommon (≥1/1,000 to <1/100) | Post-marketing safety experience (frequency not known) |
|---|---|---|---|---|
| Infections and infestations | Injection site abscess | |||
| Metabolism and nutrition disorders | Hypoglycaemia, decreased appetite**, hyperglycaemia, diabetes mellitus | |||
| Psychiatric disorders | Insomnia* | |||
| Nervous system disorders | Dizziness, headache, lethargy** | |||
| Cardiac disorders | Sinus bradycardia* | |||
| Vascular disorders | Hot flushes* | |||
| Gastrointestinal disorders | Diarrhoea, loose stools*, abdominal pain | Nausea, vomiting, constipation, flatulence, abdominal distension, abdominal discomfort*, dyspepsia, steatorrhoea** | Faeces discoloured* | Pancreatitis |
| Hepatobiliary disorders | Cholelithiasis | Biliary dilatation* | Cholecystitis, cholangitis | |
| Musculoskeletal and connective tissue disorders | Musculoskeletal pain**, myalgia** | |||
| Skin and subcutaneous tissue disorders | Alopecia, hypotrichosis* | |||
| General disorders and administration site conditions | Asthenia, fatigue, injection site reactions (pain, mass, induration, nodule, pruritus) | |||
| Investigations | ALAT increased*, ASAT abnormal*, ALAT abnormal*, blood bilirubin increased*, blood glucose increased*, glycosylated haemoglobin increased*, weight decreased, pancreatic enzymes decreased** | ASAT increased*, blood alkaline phosphatase increased*, blood bilirubin abnormal*, blood sodium decreased* | ||
| Immune system disorders | Allergic reactions (including angioedema, anaphylaxis, hypersensitivity) |
* based on a pool of studies conducted in acromegalic patients
** based on a pool of studies conducted in patients with GEP-NETs
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
